However, Kroeger and colleagues reported that the prognostic benefit of CD8(+) TILs in patients with ovarian cancer was limited and was only achieved in the presence of PCs, CD20+ TILs and CD4+ TILs (38). This evidence concerns the gene CD8A and ovarian carcinoma.